Investigational Drug Information for Vabicaserin
✉ Email this page to a colleague
What is the drug development status for Vabicaserin?
Vabicaserin is an investigational drug.
There have been 4 clinical trials for Vabicaserin.
The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2008.
The most common disease conditions in clinical trials are Schizophrenia and [disabled in preview]. The leading clinical trial sponsors are Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer, and [disabled in preview].
Summary for Vabicaserin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 150 |
| WIPO Patent Applications | 111 |
| Japanese Patent Applications | 9 |
| Clinical Trial Progress | Phase 2 (2008-11-01) |
| Vendors | 17 |
Recent Clinical Trials for Vabicaserin
| Title | Sponsor | Phase |
|---|---|---|
| Comparative Formulation Study of Vabicaserin | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 |
| Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 2 |
| Study Evaluating Vabicaserin in Subjects With Schizophrenia | Pfizer | Phase 2 |
Clinical Trial Summary for Vabicaserin
Top disease conditions for Vabicaserin
Top clinical trial sponsors for Vabicaserin
US Patents for Vabicaserin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
